-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Existing research evidence suggests that Janus-related kinase (JAK) inhibitors are therapeutic targets worthy of rapid study.
study evaluated the efficacy and safety of JAK1/2 inhibitor Rusolitinib in the treatment of coronavirus disease in 2019.
conducted a forward-looking, multi-center, single-blind, randomized controlled Phase II trial in patients with severe COVID-19.
43 patients were randomly assigned (1:1) to rusolitinib joint standard care treatment (22 patients) or to a placebo group (21 patients) based on standard care treatment.
excluded 2 patients from the Rusolitinie group (1 did not meet the criteria and 1 withdrew their consent), they were eventually included in 20 patients in the intervention group and 21 patients in the control group.
results, in patients with COVID-19 severity, although the clinical improvement of Rusolitini recipients was faster, the treatment of Rusolitini combined standard care was not associated with clinical improvement in severe patients.
results of computer fault scans showed that 18 (90%) patients in the Rusolitini group improved on the 14th day, compared with 13 patients (61.9%) in the control group (P.0495).
three patients in the control group died of respiratory failure, with a total mortality rate of 14.3 per cent over 28 days, and none in the Rusolitini group died.
rusolitinium is well resistant, low toxicity and has no new safety warning signs.
levels of seven cytokines in the Rusolitinie group were significantly lower than in the control group.
, although no statistical differences were observed, the clinical improvement of Rusolitini recipients was faster.
significant improvement in chest computer litacle scans in the Rusolitinie group, faster recovery of lymphocyte reduction and good side effects are encouraging and useful for future trials to test Rusolitinini's efficacy in a larger population.
.